NL300918I2 - Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride - Google Patents
Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride Download PDFInfo
- Publication number
- NL300918I2 NL300918I2 NL300918C NL300918C NL300918I2 NL 300918 I2 NL300918 I2 NL 300918I2 NL 300918 C NL300918 C NL 300918C NL 300918 C NL300918 C NL 300918C NL 300918 I2 NL300918 I2 NL 300918I2
- Authority
- NL
- Netherlands
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- bupropion
- hydrochloride
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 title 1
- IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 title 1
- 229960001058 bupropion Drugs 0.000 title 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title 1
- 229960004367 bupropion hydrochloride Drugs 0.000 title 1
- 229960003086 naltrexone Drugs 0.000 title 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000001796 Melanocortin 4 receptors Human genes 0.000 abstract 2
- 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 abstract 2
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 abstract 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000004580 weight loss Effects 0.000 abstract 2
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46683803P | 2003-04-29 | 2003-04-29 | |
| EP07116330A EP1870096A3 (en) | 2003-04-29 | 2004-04-21 | Compositions for affecting weight loss |
| EP04760321A EP1617832B1 (en) | 2003-04-29 | 2004-04-21 | Compositions for affecting weight loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300918I1 NL300918I1 (nl) | 2017-12-14 |
| NL300918I2 true NL300918I2 (nl) | 2018-01-09 |
Family
ID=38719840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300918C NL300918I2 (nl) | 2003-04-29 | 2017-12-11 | Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1870096A3 (enExample) |
| BE (1) | BE2017C064I2 (enExample) |
| CY (2) | CY1119418T1 (enExample) |
| FR (1) | FR17C1058I2 (enExample) |
| LU (1) | LUC00054I2 (enExample) |
| NL (1) | NL300918I2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012111011A2 (en) | 2011-02-16 | 2012-08-23 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
| CA2899455C (en) | 2013-01-30 | 2021-06-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217353A (en) * | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
| DK0782445T3 (da) * | 1994-09-19 | 2002-05-06 | Bristol Myers Squibb Pharma Co | Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed |
| DE69736928T2 (de) * | 1996-05-07 | 2007-06-28 | Pliva Istrazivanje I Razvoj D.O.O. | Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus |
| EP1051167A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| WO2001052851A1 (en) * | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| PT1326630E (pt) * | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
| US20030087896A1 (en) * | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| US20040102440A1 (en) * | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| CN101310723A (zh) * | 2002-05-17 | 2008-11-26 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
-
2004
- 2004-04-21 EP EP07116330A patent/EP1870096A3/en not_active Withdrawn
-
2017
- 2017-09-05 CY CY20171100932T patent/CY1119418T1/el unknown
- 2017-12-08 FR FR17C1058C patent/FR17C1058I2/fr active Active
- 2017-12-11 CY CY2017041C patent/CY2017041I1/el unknown
- 2017-12-11 LU LU00054C patent/LUC00054I2/en unknown
- 2017-12-11 NL NL300918C patent/NL300918I2/nl unknown
- 2017-12-12 BE BE2017C064C patent/BE2017C064I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1870096A2 (en) | 2007-12-26 |
| FR17C1058I2 (fr) | 2019-01-11 |
| BE2017C064I2 (enExample) | 2023-08-09 |
| LUC00054I1 (enExample) | 2017-12-13 |
| CY2017041I2 (el) | 2018-09-05 |
| CY2017041I1 (el) | 2018-09-05 |
| NL300918I1 (nl) | 2017-12-14 |
| LUC00054I2 (enExample) | 2018-02-21 |
| CY1119418T1 (el) | 2018-03-07 |
| EP1870096A3 (en) | 2011-04-20 |
| FR17C1058I1 (enExample) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1700052I1 (hu) | Opioid antagonistát és bupropiont tartalmazó készítmények súlyvesztés befolyásolására | |
| WO2007089318A3 (en) | Compositions and methods for reducing food cravings | |
| WO2001037785A3 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
| MY130803A (en) | New quinuclidine amide derivatives | |
| WO2007088489A3 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| DE50309807D1 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| WO2007061828A3 (en) | Pharmaceutical compositions comprising buprenorphine | |
| DE602004024742D1 (de) | Handschuh zum Schutz gegen Schwingungen und Verfahren zu seiner Herstellung | |
| PL374832A1 (pl) | Nowe podstawione benzoimidazolowe postacie dawkowe i sposoby ich stosowania | |
| CA2389650A1 (en) | Composition for treatment of constipation and irritable bowel syndrome | |
| EE200300151A (et) | Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks | |
| DE60234183D1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| EE200300342A (et) | Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine | |
| WO2004002463A3 (en) | Method of promoting smoking cessation | |
| LU91882I2 (fr) | Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) | |
| SI1581518T1 (sl) | Substituirani 1-piperidin-4-il-4-pirolidin-3-il-piperazinski derivati in njihova uporaba kot nevrokininski antagonisti | |
| PL1692102T3 (pl) | Kompozycje i sposoby do wykrywania i leczenia chorób i stanów związanych z receptorami chemokiny | |
| LU91883I2 (fr) | Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) | |
| NL300918I2 (nl) | Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride | |
| WO2007092157A9 (en) | 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline | |
| EP1262196A3 (en) | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | |
| UA92380C2 (ru) | Применение комбинации морфина и по меньшей мере одного опиатного антагониста для заместительной терапии опиатозависимых и героинозависимых лиц | |
| PT1696913E (pt) | Composição farmacêutica de vinflunina destinada à administração parenteral, processo de preparação e utilização | |
| JP2004269517A5 (enExample) | ||
| ATE505465T1 (de) | Chroman- und thiochroman-3-yl-1,3- dihydroimidazole als hemmer der dopamin-beta- hydroxylase und verfahren zu ihrer herstellung |